Beleodaq is indicated for the treatment of patients with relapsed or refractory Peripheral T- Cell Lymphoma (PTCL)

INN:

Subtype:

PTCL (PTCL)

License:

FDA

Class:

HDAC inhibitor

R/R

PIhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf 

1. Approved Labelling

Beleodaq is indicated for the treatment of patients with relapsed or refractory Peripheral T- Cell Lymphoma (PTCL). 

2. Treatment Regimen 

The recommended dosage of Beleodaq is 1,000 mg/m2 administered over 30 minutes by intravenous infusion once daily on Days 1-5 of a 21-day cycle. Cycles can be repeated every 21 days until disease progression or unacceptable toxicity.

3. AE/Warnings

Please see section 5 of the PI.

 

Disclaimer: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.